Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Arecor Therapeutics Plc LSE:AREC London Ordinary Share GB00BMWLM973 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 265.00 250.00 280.00 265.00 265.00 265.00 0.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.2 -6.9 -0.3 - 74

Arecor Therapeutics Share Discussion Threads

Showing 201 to 225 of 225 messages
Chat Pages: 9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
13/9/2022
14:05
Nice article on Arecor:- https://twitter.com/arecor_plc/status/1569660103200051200 Best regards SBP
stupidboypike
09/8/2022
10:58
sn, on reflection, you are quite right, they couldn't go it alone with this. The RNS does state:- Using its proprietary Arestat (TM) technology, Arecor has developed novel formulations enabling a high-concentration adalimumab product (100 mg/mL or higher) with excellent stability. So there is a possibility that we are achieving higher concentration and/or better stability than best in class. Whether that would be enough to attract a partner is anyone's guess. The nice thing about Arecor (in my opinion) is that they have so many irons in the fire we are not totally dependent on any one of them. Best regards SBP
stupidboypike
09/8/2022
10:36
Well, they've been at it for a while - it was mentioned in the AIM Admission document in the list of patent families. There are now quite a few of these high concentration biosimilars already on the market, the best-known being Yuflyma, and I don't think Arecor has the resources to go it alone in a niche that's already well-filled.
supernumerary
09/8/2022
09:23
I don't think so. I would suspect they would develop the candidate through the initial phases themselves.
jimbo123elf
09/8/2022
09:22
supernumeracy, I don't believe there have been any announcements about partnership on this. In my view, AT220 is the only one it could have been, but this is explicitly mentioned in the RNS as another example of a different biosimilar. So I guess they will be looking for a partner, unless they are planning to push it out in Europe with Tetris? Exciting times. Best regards SBP
stupidboypike
09/8/2022
08:48
Is this partnered with anybody?
supernumerary
09/8/2022
08:18
Two new patents for novel formulations of high-concentration adalimumab (Humira has global sales of $21bn).
jimbo123elf
05/8/2022
13:50
I was on the call yesterday, and my conclusion was that this business combination makes perfect sense for Arecor.
jimbo123elf
04/8/2022
11:08
TR1 - Lombard Odier: 5.32%
jimbo123elf
02/8/2022
15:18
shortlisted for a @businessweekly Award in the disruptive tech category! https://twitter.com/arecor_plc/status/1554471171873292290 All good stuff. Best regards SBP
stupidboypike
02/8/2022
12:11
see new Trinity Delta research note on AREC (issued yesterday) https://www.trinitydelta.org/research-notes/acquisition-of-tetris-pharma-and-6m-equity-raise/
timbo003
01/8/2022
16:13
Glad you got some timbo, I've been looking at the deal for a while now and I do think on balance it looks very good news. I'm already very overweight in Arecor, so I haven't taken any in this round, although I think 300p with EIS relief is a very good price. Best regards SBP
stupidboypike
01/8/2022
15:59
I managed to pick up a few (EIS) shares in the Book build, but was scaled back by 64%, however given that the share register for Arecor reads like a who's who in the VCT world and VCTs had another bumper fund raising year last tax year, I was expecting a larger scale back than that.
timbo003
01/8/2022
15:05
I think this is probably a nice bit of business for Arecor executed efficiently. We now have at least 12 approved products being sold to market (including the generics?) which complement the portfolio, and the added skillset of the Tetris team.
jimbo123elf
01/8/2022
09:29
SBP Agreed I applied for a few EIS shares earlier this morning in the book build, have just been informed that there will be scale pack on the EIS portion of the fund raise, so I'm just hoping it will only be modest.
timbo003
01/8/2022
09:24
Interestingly I remember hearing that the glucagon development had been put on hold as another company was making good progress with it. I guess that is this one. This could be a very smart move by Arecor. Not thrilled about the dilution, but if they have got it right that will be a very sensible price to pay I think. I also like the fact that half the payment is not due until/unless the acquired company becomes profitable. Best regards SBP
stupidboypike
01/8/2022
08:39
Here are a few notes I took at the Oxford VCTs AGM back in July 2017 where Arecor were presenting: https://www.lemonfool.co.uk/viewtopic.php?t=6265 Arecor: Presenter: Sarah Howell (CEO) Web site: http://www.arecor.com/ Presentation slide set: https://tinyurl.com/ybagu49f Arecor began as a spin out from Unilever in 2007. The company specialises in formulating (and reformulating) drugs for parenteral administration, with a focus on Biologics. Their technology can enable drugs which are currently marketed as lyophilised powders to be formulated as stable liquids (for convenience), or to produce higher concentrations of drug in parenteral formulations (i.e. lower injection volumes), or to enable combinations of drugs which may otherwise be incompatible. There are two arms to the business: * Reformulation: Arecor can reformulate an existing drug on behalf of a client (typically a large pharma) on a fee for service plus royalties basis. This part of the business is revenue generating. * Diabetes: This is in house development which focuses on developing stable liquid glucagon solutions suitable for parenteral administration, for example via a PEN device for emergency use (similar to an epinephrine PEN), or an external pump (artificial pancreas) for everyday control of insulin and sugar levels in type 1 diabetics. The company is currently raising funds for the next stages of development
timbo003
01/8/2022
08:22
It is also noteworthy that if you rewind a few years, Arecor's lead project concerned an improved formulation for Glucagen which was deprioritised in favour of the improved insulin projects, so presumably the Glucagen project will now come to the fore again?
timbo003
01/8/2022
07:55
First reaction: looks highly complementary. However placing is c10% increase in share capital, but they are targeting a v small discount albeit to a share price which has reduced a lot in last couple of weeks. Potentially large deferred consideration which will have to be watched.
18bt
20/7/2022
10:19
Arecor featured in "Best of British" series:- https://twitter.com/arecor_plc/status/1549684303533047811 Best regards SBP
stupidboypike
15/7/2022
15:07
Thank you SBP
drdre
15/7/2022
13:58
Hi DrDre, At the time of the IPO, I believe it was stated that the funds from the IPO were sufficient to take the company to profitability in 2025. Obviously a lot of the cash outflow at the moment is the trails of the 2 insulin products, this should come to an end this year, so I am not overly concerned about the cash position personally. Best regards SBP
stupidboypike
15/7/2022
11:42
This is on my watchlist after the FY presentation. My only concern given the macro situation and markets, is cash. They had Cash and cash equivalents of £18.3 million Dec 2021 and as of 30 June 2022 it was £13.7 million. That is a cash runway of around 16-18 months? Really like the company but just wary of that - cash on the balance sheet, especially in this sector, is king. I also appreciate a lot can happen in that timeframe too in terms of partnership deals etc so was just wondering what others views were?
drdre
15/7/2022
10:02
Nice write up in Business weekly:- hxxps://www.businessweekly.co.uk/news/local-sharewatch/arecor-goes-strength-strength Best regards SBP
stupidboypike
22/6/2022
11:07
Nice to see Arecor in the business weekly "killer 50" list. https://twitter.com/arecor_plc/status/1539514135284695040 Best regards SBP
stupidboypike
Chat Pages: 9  8  7  6  5  4  3  2  1
ADVFN Advertorial
Your Recent History
LSE
AREC
Arecor The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220925 20:55:34